Form 4: Alexander Denner and Sarissa Capital Management Report Changes in Ironwood Pharmaceuticals Ownership

Alexander Denner and Sarissa Capital Management report changes in beneficial ownership of Ironwood Pharmaceuticals stock, including the acquisition of shares and indirect ownership through Sarissa Capital's managed funds.

Summary

• Alexander Denner, a director and 10% owner of Ironwood Pharmaceuticals, along with Sarissa Capital Management, reported changes in beneficial ownership.
• Denner acquired 2,572 shares of Class A Common Stock on June 15, 2024, at $0 per share, issued pursuant to the Second Amended and Restated Non-employee Director Compensation Policy.
• Sarissa Capital Management LP is reported to indirectly beneficially own 16,390,000 shares.
• Denner may be deemed to indirectly beneficially own shares held by Sarissa Capital Management LP and the Sarissa Funds, for which Sarissa Capital serves as investment advisor.
• Both Denner and Sarissa Capital Management LP disclaim beneficial ownership of these shares except to the extent of their pecuniary interest therein.

Sentiment

Score: 6

Explanation: The document is a standard regulatory filing, indicating routine transactions. The sentiment is neutral as it primarily reports changes in ownership without expressing a strong positive or negative outlook.

Positives

• Alexander Denner's acquisition of shares may signal confidence in Ironwood Pharmaceuticals.
• The shares were issued under the director compensation policy, aligning director interests with shareholders.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.

Stakeholder Impact

• The change in ownership may be of interest to shareholders, as it reflects insider activity.
• The filing ensures transparency and compliance with SEC regulations.

Key Dates